Uncover key drivers, emerging technologies, and competitive movements shaping the chemotherapy induced peripheral neuropathy treatment market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Chemotherapy Induced Peripheral Neuropathy Treatment Market between 2026 and 2030?

The chemotherapy induced peripheral neuropathy treatment market size has seen strong expansion in recent years. It is forecast to grow from $1.75 billion in 2025 to $1.86 billion in 2026, with a compound annual growth rate (CAGR) of 6.2%. In past periods, this growth has been influenced by the increased application of neurotoxic chemotherapy agents, higher cancer survival rates, a greater understanding of chemotherapy side effects, the availability of various symptomatic treatment options, and the expansion of oncology care infrastructure.

The chemotherapy induced peripheral neuropathy treatment market is expected to experience substantial growth in the upcoming years. It is projected to expand to $2.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.2%. This anticipated growth can be attributed to increased investment in targeted neuropathy therapies, a heightened focus on personalized oncology supportive care, the expansion of clinical trials for CIPN drugs, a growing demand for treatments that improve quality of life, and advancements in biomarker-based diagnosis. Significant trends during the forecast period include an increasing emphasis on neuroprotective drug development, a rising adoption of combination therapy approaches, a stronger focus on early diagnosis and symptom management, the broadening of personalized treatment protocols, and increased clinical research concerning CIPN management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp

Which Drivers Are Expected To Impact The Chemotherapy Induced Peripheral Neuropathy Treatment Market During The Forecast Period?

The increasing occurrence of cancer is expected to drive the expansion of the chemotherapy-induced peripheral neuropathy treatment market. Cancer is characterized as a disease involving the uncontrolled proliferation and dissemination of abnormal cells throughout the body. Chemotherapy-induced peripheral neuropathy is a possible adverse effect associated with certain chemotherapy drugs employed in cancer treatment. The chemotherapy-induced peripheral neuropathy treatment market is poised for growth as there is an escalation in cancer cases worldwide. For example, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which equals over 450 cases daily, with males representing approximately 55% of these diagnoses. Therefore, the rising prevalence of cancers is fueling the growth of the chemotherapy-induced peripheral neuropathy treatment market.

How Is The Chemotherapy Induced Peripheral Neuropathy Treatment Market Divided Into Segments?

The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented –

1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes

2) By Treatment: Medication, Therapy, Other Treatments

3) By Drug Type: Branded, Generic

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Research Institutes, Specialty Clinics

Subsegments:

1) By Nerve Protective Therapy: Vitamin B Complex, Alpha-Lipoic Acid, Acetyl-L-Carnitine

2) By Anti-Inflammatory Therapy: Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

3) By Neurotransmitter Based Therapy: Gabapentin, Pregabalin, Duloxetine

4) By Antioxidant: N-acetylcysteine, Glutathione, Coenzyme Q10

5) By Other Drug Classes: Topical Treatments, Opioids, Herbal Remedies

Which Trends Are Expected To Influence The Chemotherapy Induced Peripheral Neuropathy Treatment Market In The Upcoming Years?

Leading companies in the chemotherapy-induced peripheral neuropathy treatment market are prioritizing the development of new products to strengthen their observational power and maintain their market presence. For example, in March 2023, AlgoTx, a clinical-stage firm dedicated to managing complex pain, revealed that the FDA had approved the Investigational New Drug Application (IND) for ATX01, its Phase 2 first-in-class candidate. This groundbreaking treatment is designed for individuals with erythromelalgia. Simultaneously, the initial patients in the ATX01 for the Pain of Chemotherapy (ACT) study, which focuses on chemotherapy-induced peripheral neuropathy (CIPN), have begun randomization. The FDA has granted fast-track designation to both programs.

Which Leading Companies Dominate The Chemotherapy Induced Peripheral Neuropathy Treatment Market Share?

Major companies operating in the chemotherapy induced peripheral neuropathy treatment market are Midatech Pharma PLC, Novartis AG, Hoffmann-La Roche Ltd., Lee’s Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, WEX Pharmaceuticals Inc., MediciNova Inc., Solasia Pharma K.K., ESTEVE, Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation, ChromaDex Inc., Eurofins Advinus, Asahi Kasei Corporation, WinSanTor Inc., Apollo Endosurgery Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Chemotherapy Induced Peripheral Neuropathy Treatment Market?

North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2025. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11967&type=smp

Browse Through More Reports Similar to the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2026, By The Business Research Company

Neuropathic Pain Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Peripheral Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Diabetic Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model